Drug resistance in metastatic castration-resistant prostate cancer.
about
Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristicsDAB2IP in cancerChemotherapy and its evolving role in the management of advanced prostate cancerAnti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-reviewRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerCellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agentsTumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments.Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxiaDocetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate CancerLemur Tyrosine Kinase 2, a novel target in prostate cancer therapyA phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancerPrognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsGenistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.Clinical and biological significance of KISS1 expression in prostate cancer.Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerPrognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate CancerCo-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer GrowthMathematical Modelling and Prediction of the Effect of Chemotherapy on Cancer Cells.Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip.The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.Overcoming drug resistance and treating advanced prostate cancerMolecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxelCurrent and emerging therapies for bone metastatic castration-resistant prostate cancer.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agentsRole of hormonal therapy for prostate cancer: perspective from Japanese experiences.The mechanism of DAB2IP in chemoresistance of prostate cancer cells.Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer.The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patientsThe mechanisms of chansu in inducing efficient apoptosis in colon cancer cells.Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspectiveEnzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
P2860
Q26773613-A8E4D1B1-6B2A-4CEC-BC7F-CBE558C43CB9Q26776456-F160E70D-A672-41A1-9C73-FDF7FE6AAE8DQ27008883-B72A2D46-AA83-426D-A9A4-F9047EF279F4Q28067001-FF459CD3-B916-4588-BBA5-C04DC26C1D8DQ28075965-3259A5E5-25CC-415D-848C-A5F871416862Q28383284-841228CE-3C6B-4CB5-B7A4-B8CD72818A01Q30822011-C51E8958-EDCD-4BF6-9AD0-B0F0B4DCAC93Q33584594-BBC04D75-0A51-4597-BC31-A1BA69D21C13Q33819310-51908541-84B9-4829-8B57-3805FCFD5F2AQ33885738-5AFCEAD4-FCBB-49B0-AD47-6EB2B15708CFQ34154674-D2507E79-512D-4CA4-AB9F-59CCD96C1B4BQ34468270-827FFDC4-139D-46B7-9B3B-27580FA863EFQ34477201-E2200127-46AF-4D8B-99B4-91A6964C29E1Q34477815-F09F3784-8B0D-4376-B2F1-D261B82253B8Q34569689-28AE1E95-09B1-4BF9-A8A2-8110DF7AC467Q35114920-BD8C9E43-0083-4DDF-9E04-26D3575ED91BQ35551899-10EFF139-A0AE-4202-8006-EF0F09BE362DQ35598295-906C2975-2EC5-432F-B2F9-F2AB92BDB44BQ35653741-3BBB2B7E-51A7-4B71-8D97-08DA7AB80256Q35658479-F0102ED2-20F3-4BA8-9C82-5F8248DCC9C8Q35823157-93B749B6-9B7A-43E3-85C0-570BB5876BE7Q35844645-E944CF5C-7B1B-45A7-BE21-8F4F1741C631Q35952025-C0F7650A-C216-4144-AF87-B570C35AAAC4Q35956276-B2DE3006-875B-495B-828D-FA234EBEBA6FQ35971011-F82677E7-72FA-4DE1-A8E1-628C7B142D4BQ35982218-DF16B6B5-3A97-40CB-B9E9-44879880BFEBQ36002786-26A15379-B60C-43BA-B71C-CC389CECDD12Q36277902-4E77F9D5-8D0C-4E12-848E-89B671ED26B1Q36294460-17E5CDFF-2F78-4F23-92E8-AF3EE235C9E8Q36328812-9FF99827-4729-45FB-89E1-8EA68B559C80Q36356460-43EC77CA-B1A7-4FB1-86B3-E5A4A8E85ACBQ36358303-75B544B5-C415-4DEB-8BF2-9FC1F280FCF5Q36414184-EBEADBAA-9354-4859-AA37-288D8402DED6Q36450795-D5FDFA5F-FD95-4872-8E26-18DA1CA1C625Q36725756-84C1BCC6-4222-418F-9459-22565A49CCAFQ36752045-189169F7-84B3-4963-B4BC-69D3E1B610F1Q36907840-9054DC24-2339-4895-A341-D12E429963F7Q36931329-877CA202-9C78-4A29-B57A-84787290800DQ37044229-05A073B0-D82F-4446-85CF-45422F3AFF55Q37146546-D2F306DF-DE37-42F8-8AA6-BDCDD03A5E88
P2860
Drug resistance in metastatic castration-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug resistance in metastatic castration-resistant prostate cancer.
@ast
Drug resistance in metastatic castration-resistant prostate cancer.
@en
Drug resistance in metastatic castration-resistant prostate cancer.
@nl
type
label
Drug resistance in metastatic castration-resistant prostate cancer.
@ast
Drug resistance in metastatic castration-resistant prostate cancer.
@en
Drug resistance in metastatic castration-resistant prostate cancer.
@nl
prefLabel
Drug resistance in metastatic castration-resistant prostate cancer.
@ast
Drug resistance in metastatic castration-resistant prostate cancer.
@en
Drug resistance in metastatic castration-resistant prostate cancer.
@nl
P1476
Drug resistance in metastatic castration-resistant prostate cancer.
@en
P2093
Bostjan Seruga
Ian F Tannock
P2860
P356
10.1038/NRCLINONC.2010.136
P407
P577
2010-09-21T00:00:00Z